<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01402115</url>
  </required_header>
  <id_info>
    <org_study_id>Glu-POLYCAN-001</org_study_id>
    <nct_id>NCT01402115</nct_id>
  </id_info>
  <brief_title>A 12-week Human Trial to Compare the Efficacy and Safety of Polycan on Bone Metabolism</brief_title>
  <official_title>Efficacy and Safety Study of Polycan on Bone Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chonbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chonbuk National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Beta-glucans are polysaccharides consisting of glucose residue jointed by beta linkage. They
      are found at a high level in the cell wall of fungi, yeast, oat, barley, bacteria, as well as
      various mushroom. Studies have reported that extract of mushroom (Pleurotus eryngii) can
      prevent the bone loss caused by estrogen deficiency. Furthermore, polycan (a purified
      β-glucan from Aureobasidium pullulans) has been reported to exhibit osteoporosis preventing
      effects. However, no investigation has been conducted on the effect of polycan on bone health
      in perimenopausal women.

      Therefore, in this study, we investigated the effect of polycan on biochemical markers of
      bone metabolism in Korean perimenopausal women.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in DPD(Deoxypyridinoline)</measure>
    <time_frame>12weeks</time_frame>
    <description>DPD(Deoxypyridinoline) was measured in study visit 1(0 week) and visit 3(12 week).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in OSC(Osteocalcin)</measure>
    <time_frame>12weeks</time_frame>
    <description>OSC(Osteocalcin) was measured in study visit 1(0 week) and visit 3(12 week).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in CTx(Collagen Type 1 Cross-linked C-telopeptide)</measure>
    <time_frame>12weeks</time_frame>
    <description>CTx(collagen type 1 cross-linked C-telopeptide) was measured in study visit 1(0 week) and visit 3(12 week).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in bALP(Bone-specific Alkaline Phosphatase)</measure>
    <time_frame>12weeks</time_frame>
    <description>bALP(bone-specific alkaline phosphatase) was measured in study visit 1(0 week) and visit 3(12 week).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in PTH(Parathyroid Hormone)</measure>
    <time_frame>12weeks</time_frame>
    <description>PTH(parathyroid hormone) was measured in study visit 1(0 week) and visit 3(12 week).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Bone Health in Perimenopausal Women</condition>
  <arm_group>
    <arm_group_label>Polycan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polycan 150mg for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 15mg for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Polycan</intervention_name>
    <description>polycan 150 mg/d for 12 weeks</description>
    <arm_group_label>Polycan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 150mg/d for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  They were required to have reduced bone density but no evidence of osteoporosis or
             osteopenia by Dual-emission X-ray absorptiometry (DEXA) scan (T ≥ -1.0 in the lumbar
             spine).

          -  Perimenopausal women : aged 40-70

        Exclusion Criteria:

          -  Women with a body mass index (BMI) &gt;30 kg/m2 or who were being treated with estrogens,
             corticosteroids, or bisphosphonates, or who had significant illness affecting bone
             metabolism were excluded
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dal-Sik Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Healthcare claims and management; Chonbuk National university</name>
      <address>
        <city>Jeonju</city>
        <state>Jeollabuk-do</state>
        <zip>560-822</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2011</study_first_submitted>
  <study_first_submitted_qc>July 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2011</study_first_posted>
  <results_first_submitted>July 26, 2012</results_first_submitted>
  <results_first_submitted_qc>September 5, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 5, 2012</results_first_posted>
  <last_update_submitted>October 10, 2012</last_update_submitted>
  <last_update_submitted_qc>October 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chonbuk National University Hospital</investigator_affiliation>
    <investigator_full_name>Soo-Wan Chae</investigator_full_name>
    <investigator_title>Clinical Trial Center for Functional Foods</investigator_title>
  </responsible_party>
  <keyword>Polycan</keyword>
  <keyword>Bone metabolism</keyword>
  <keyword>Osteocalcin</keyword>
  <keyword>Deoxypyridinoline</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited through local advertising and doctor referrals from hospital outpatients and general practice clinics.</recruitment_details>
      <pre_assignment_details>The criteria were an age from 40 to 70 years, They were required to have reduced bone density but no evidence of osteoporosis or osteopenia by Dual-emission X-ray absorptiometry (DEXA) scan (T ≥ -1.0 in the lumbar spine).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Polycan</title>
          <description>Polycan 150mg for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo 15mg for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Polycan</title>
          <description>Polycan 150mg for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo 15mg for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.8" spread="6.3"/>
                    <measurement group_id="B2" value="52.9" spread="5.8"/>
                    <measurement group_id="B3" value="52.8" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in DPD(Deoxypyridinoline)</title>
        <description>DPD(Deoxypyridinoline) was measured in study visit 1(0 week) and visit 3(12 week).</description>
        <time_frame>12weeks</time_frame>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Polycan</title>
            <description>Polycan 150mg for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 15mg for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in DPD(Deoxypyridinoline)</title>
          <description>DPD(Deoxypyridinoline) was measured in study visit 1(0 week) and visit 3(12 week).</description>
          <population>per protocol analysis</population>
          <units>nanoMolar DPD per milliMolar creatine</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="2.2"/>
                    <measurement group_id="O2" value="6.4" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="2.1"/>
                    <measurement group_id="O2" value="5.6" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in OSC(Osteocalcin)</title>
        <description>OSC(Osteocalcin) was measured in study visit 1(0 week) and visit 3(12 week).</description>
        <time_frame>12weeks</time_frame>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Polycan</title>
            <description>Polycan 150mg for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 15mg for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in OSC(Osteocalcin)</title>
          <description>OSC(Osteocalcin) was measured in study visit 1(0 week) and visit 3(12 week).</description>
          <population>per protocol analysis</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" spread="6.8"/>
                    <measurement group_id="O2" value="14.2" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.8" spread="7.7"/>
                    <measurement group_id="O2" value="17.0" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in CTx(Collagen Type 1 Cross-linked C-telopeptide)</title>
        <description>CTx(collagen type 1 cross-linked C-telopeptide) was measured in study visit 1(0 week) and visit 3(12 week).</description>
        <time_frame>12weeks</time_frame>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Polycan</title>
            <description>Polycan 150mg for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 15mg for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in CTx(Collagen Type 1 Cross-linked C-telopeptide)</title>
          <description>CTx(collagen type 1 cross-linked C-telopeptide) was measured in study visit 1(0 week) and visit 3(12 week).</description>
          <population>per protocol analysis</population>
          <units>µg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="344" spread="183"/>
                    <measurement group_id="O2" value="314" spread="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="341" spread="171"/>
                    <measurement group_id="O2" value="301" spread="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in bALP(Bone-specific Alkaline Phosphatase)</title>
        <description>bALP(bone-specific alkaline phosphatase) was measured in study visit 1(0 week) and visit 3(12 week).</description>
        <time_frame>12weeks</time_frame>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Polycan</title>
            <description>Polycan 150mg for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 15mg for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in bALP(Bone-specific Alkaline Phosphatase)</title>
          <description>bALP(bone-specific alkaline phosphatase) was measured in study visit 1(0 week) and visit 3(12 week).</description>
          <population>per protocol analysis</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8" spread="11.3"/>
                    <measurement group_id="O2" value="28.6" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8" spread="11.7"/>
                    <measurement group_id="O2" value="29.8" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in PTH(Parathyroid Hormone)</title>
        <description>PTH(parathyroid hormone) was measured in study visit 1(0 week) and visit 3(12 week).</description>
        <time_frame>12weeks</time_frame>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Polycan</title>
            <description>Polycan 150mg for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 15mg for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in PTH(Parathyroid Hormone)</title>
          <description>PTH(parathyroid hormone) was measured in study visit 1(0 week) and visit 3(12 week).</description>
          <population>per protocol analysis</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8" spread="10.4"/>
                    <measurement group_id="O2" value="31.1" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.0" spread="9.3"/>
                    <measurement group_id="O2" value="33.6" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Serious and/or other [non-serious] adverse events were not collected/assessed</desc>
      <group_list>
        <group group_id="E1">
          <title>Polycan</title>
          <description>Polycan 150mg for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo 15mg for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Dal-Sik Kim, MD</name_or_title>
      <organization>Clinical Trial Center for Functional Foods; Chonbuk National University Hospital</organization>
      <phone>82-63-276-8284</phone>
      <email>dskim@chonbuk.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

